

## Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023

### Description

October 31, 2023 08:00 ET

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women's Health Inc. ("Aspira"), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 p.m. Eastern Time. Details for the call are as follows:

#### Conference call & Webcast Details:

Date: Monday, November 13  
Time: 4:30 p.m. Eastern Time  
Toll Free: 1-877-407-4018  
International: 1-201-689-8471  
Webcast: [click HERE](#)  
Call me™: [click HERE](#)

Participants can use Guest dial-in numbers above and be answered by an operator OR participants can click the Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to the scheduled start time.

A replay of the webcast will also be available on the [Events & Presentation](#) page of the Aspira Women's Health Investor Relations website.

#### About Aspira Women's Health Inc.

Aspira Women's Health Inc. is transforming women's gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite<sup>SM</sup>, which includes OvaWatch<sup>SM</sup>, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus<sup>®</sup> combines our FDA-cleared products,

Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.

EndoCheck<sup>SM</sup>, Aspira's first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at [www.aspirawh.com](http://www.aspirawh.com).

***Investor Relations Contact:***

Monique Kosse  
Managing Director  
LifeSci Advisors, LLC  
Tel: 212-915-3820